{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T20:02:53Z","timestamp":1771272173388,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013733","name":"Ipsen Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03439-6","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T07:47:32Z","timestamp":1764748052000},"page":"600-614","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic Burden of Primary Biliary Cholangitis by Line of Therapy in the United States"],"prefix":"10.1007","volume":"43","author":[{"given":"Sonal","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-7786","authenticated-orcid":false,"given":"Nisreen","family":"Shamseddine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongni","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shravanthi","family":"Seshasayee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"10266","key":"3439_CR1","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(20)31607-X","volume":"396","author":"A Lleo","year":"2020","unstructured":"Lleo A, Wang G-Q, Gershwin ME, Hirschfield GM. Primary biliary cholangitis. Lancet. 2020;396(10266):1915\u201326. https:\/\/doi.org\/10.1016\/S0140-6736(20)31607-X.","journal-title":"Lancet"},{"issue":"8","key":"3439_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cgh.2017.12.033","volume":"16","author":"M Lu","year":"2018","unstructured":"Lu M, Zhou Y, Haller IV, Romanelli RJ, VanWormer JJ, Rodriguez CV, et al. Increasing prevalence of primary biliary cholangitis and reduced mortality with treatment. Clin Gastroenterol Hepatol. 2018;16(8):1342\u201350.e1. https:\/\/doi.org\/10.1016\/j.cgh.2017.12.033.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"3439_CR3","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/2050640620919585","volume":"8","author":"A Laschtowitz","year":"2020","unstructured":"Laschtowitz A, de Veer RC, Van der Meer AJ, Schramm C. Diagnosis and treatment of primary biliary cholangitis. United Eur Gastroenterol J. 2020;8(6):667\u201374. https:\/\/doi.org\/10.1177\/2050640620919585.","journal-title":"United Eur Gastroenterol J"},{"issue":"1","key":"3439_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145\u201372. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022.","journal-title":"J Hepatol"},{"issue":"4","key":"3439_CR5","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/hep.32117","volume":"75","author":"KD Lindor","year":"2022","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases. Hepatology. 2022;75(4):1012\u20133. https:\/\/doi.org\/10.1002\/hep.32117.","journal-title":"Hepatology"},{"issue":"3","key":"3439_CR6","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/hep.22428","volume":"48","author":"C Corpechot","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, Chr\u00e9tien Y, Andr\u00e9ani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;48(3):871\u20137. https:\/\/doi.org\/10.1002\/hep.22428.","journal-title":"Hepatology"},{"key":"3439_CR7","unstructured":"United States Food and Drug Administration. OCALIVA\u00ae (obeticholic acid) Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/207999s008lbl.pdf. Accessed 14 Nov 2024."},{"issue":"suppl 1","key":"3439_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/jcag\/gwab002.041","volume":"4","author":"G Hirschfield","year":"2021","unstructured":"Hirschfield G, Jones D, Carbone M, Bowlus CL, Nevens F, Kremer AE, et al. Long-term efficacy and safety of obeticholic acid in primary biliary cholangitis: responder analysis of over 5 years of treatment in the POISE trial. J Can Assoc Gastroenterol. 2021;4(suppl 1):229\u201331.\u00a0https:\/\/doi.org\/10.1093\/jcag\/gwab002.041.","journal-title":"J Can Assoc Gastroenterol"},{"key":"3439_CR9","unstructured":"Intercept Pharmaceuticals Inc. Intercept receives complete response letter from FDA addressing OCALIVA supplemental New Drug Application (sNDA) [press release]. 2024. https:\/\/www.interceptpharma.com\/about-us\/news\/?id=2979130. Accessed 14 Nov 2024."},{"key":"3439_CR10","unstructured":"Intercept Pharmaceuticals Inc. Intercept Announces Voluntary Withdrawal of OCALIVA\u00ae for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold [press release]. 2025. https:\/\/www.interceptpharma.com\/about-us\/news\/?id=3148535."},{"issue":"6","key":"3439_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S2468-1253(19)30094-9","volume":"4","author":"M Trauner","year":"2019","unstructured":"Trauner M, Nevens F, Shiffman ML, Drenth JPH, Bowlus CL, Vargas V, et al. Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. Lancet Gastroenterol Hepatol. 2019;4(6):445\u201353. https:\/\/doi.org\/10.1016\/S2468-1253(19)30094-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3439_CR12","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019;69(1):394\u2013419. https:\/\/doi.org\/10.1002\/hep.30145.","journal-title":"Hepatology"},{"issue":"1","key":"3439_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2021.100546","volume":"27","author":"GGL Cancado","year":"2022","unstructured":"Cancado GGL, Braga MH, Ferraz MLG, Villela-Nogueira CA, Terrabuio DRB, Can\u00e7ado ELR, et al. Clinical features and treatment outcomes of primary biliary cholangitis in a highly admixed population. Ann Hepatol. 2022;27(1):100546. https:\/\/doi.org\/10.1016\/j.aohep.2021.100546.","journal-title":"Ann Hepatol"},{"key":"3439_CR14","unstructured":"United States Food and Drug Administration. FENOGLIDE Prescribing Information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022118s010lbl.pdf. Accessed 29 Oct 2024."},{"issue":"9","key":"3439_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.17235\/reed.2018.5533\/2018","volume":"110","author":"W Duan","year":"2018","unstructured":"Duan W, Ou X, Wang X, Wang Y, Zhao X, Wang Q, et al. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA. Rev Esp Enferm Dig. 2018;110(9):557\u201363. https:\/\/doi.org\/10.17235\/reed.2018.5533\/2018.","journal-title":"Rev Esp Enferm Dig"},{"issue":"2","key":"3439_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2036.2010.04512.x","volume":"33","author":"C Levy","year":"2011","unstructured":"Levy C, Peter JA, Nelson DR, Keach J, Petz J, Cabrera R, et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011;33(2):235\u201342. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04512.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"3439_CR17","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","volume":"67","author":"GM Hirschfield","year":"2018","unstructured":"Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, H\u00fcbscher S, et al. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568\u201394. https:\/\/doi.org\/10.1136\/gutjnl-2017-315259.","journal-title":"Gut"},{"key":"3439_CR18","unstructured":"Gilead. Gilead\u2019s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA. https:\/\/www.gilead.com\/news\/news-details\/2024\/gileads-livdelzi-seladelpar-granted-accelerated-approval-for-primary-biliary-cholangitis-by-us-fda. Accessed 29 Oct 2024."},{"issue":"9","key":"3439_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJMoa2312100","volume":"390","author":"GM Hirschfield","year":"2024","unstructured":"Hirschfield GM, Bowlus CL, Mayo MJ, Kremer AE, Vierling JM, Kowdley KV, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. N Engl J Med. 2024;390(9):783\u201394. https:\/\/doi.org\/10.1056\/NEJMoa2312100.","journal-title":"N Engl J Med"},{"key":"3439_CR20","unstructured":"Ipsen. Ipsen\u2019s Iqirvo\u00ae receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis. https:\/\/www.ipsen.com\/press-releases\/ipsens-iqirvo-receives-u-s-fda-accelerated-approval-as-a-first-in-class-ppar-treatment-for-primary-biliary-cholangitis\/. Accessed 29 Oct 2024."},{"issue":"9","key":"3439_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2306185","volume":"390","author":"KV Kowdley","year":"2024","unstructured":"Kowdley KV, Bowlus CL, Levy C, Akarca US, Alvares-da-Silva MR, Andreone P, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. N Engl J Med. 2024;390(9):795\u2013805. https:\/\/doi.org\/10.1056\/NEJMoa2306185.","journal-title":"N Engl J Med"},{"issue":"6","key":"3439_CR22","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","volume":"32","author":"C Corpechot","year":"2000","unstructured":"Corpechot C, Carrat F, Bonnand A-M, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology. 2000;32(6):1196\u20139. https:\/\/doi.org\/10.1053\/jhep.2000.20240.","journal-title":"Hepatology"},{"issue":"2","key":"3439_CR23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/ajg.2017.440","volume":"113","author":"MH Harms","year":"2018","unstructured":"Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. Am J Gastroenterol. 2018;113(2):254\u201364. https:\/\/doi.org\/10.1038\/ajg.2017.440.","journal-title":"Am J Gastroenterol"},{"key":"3439_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510230108","author":"GR Locke III","year":"1996","unstructured":"Locke GR III, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology. 1996. https:\/\/doi.org\/10.1002\/hep.510230108.","journal-title":"Hepatology"},{"issue":"4","key":"3439_CR25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology. 2002;123(4):1044\u201351. https:\/\/doi.org\/10.1053\/gast.2002.36027.","journal-title":"Gastroenterology"},{"issue":"1","key":"3439_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","volume":"114","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Bernstein D, Shiffman ML, Kwo P, Kim WR, Kowdley KV, et al. Diagnosis and management of primary biliary cholangitis. Am J Gastroenterol. 2019;114(1):48\u201363. https:\/\/doi.org\/10.1038\/s41395-018-0390-3.","journal-title":"Am J Gastroenterol"},{"key":"3439_CR27","doi-asserted-by":"crossref","unstructured":"Gish RG, Law A, Lingohr-Smith M, Adekunle F, Wheeler D, Velez De Villa B, et al. Primary biliary cholangitis: patient characteristics and the healthcare economic burden in the United States [AASLD abstract 1259]. Hepatology; 2020;72(suppl 1). https:\/\/doi.org\/10.1002\/hep.31578","DOI":"10.1002\/hep.31578"},{"issue":"1","key":"3439_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/hep.30174","volume":"69","author":"M Sayiner","year":"2019","unstructured":"Sayiner M, Golabi P, Stepanova M, Younossi I, Nader F, Racila A, et al. Primary biliary cholangitis in Medicare population: the impact on mortality and resource use. Hepatology. 2019;69(1):237\u201344. https:\/\/doi.org\/10.1002\/hep.30174.","journal-title":"Hepatology"},{"issue":"3","key":"3439_CR29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/hep4.1314","volume":"3","author":"O Shahab","year":"2019","unstructured":"Shahab O, Sayiner M, Paik J, Felix S, Golabi P, Younossi ZM. Burden of primary biliary cholangitis among inpatient population in the United States. Hepatol Commun. 2019;3(3):356\u201364. https:\/\/doi.org\/10.1002\/hep4.1314.","journal-title":"Hepatol Commun"},{"issue":"6","key":"3439_CR30","doi-asserted-by":"publisher","first-page":"e0179","DOI":"10.1097\/hc9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella J, John BV, Levy C. Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun. 2023;7(6):e0179. https:\/\/doi.org\/10.1097\/hc9.0000000000000179.","journal-title":"Hepatol Commun"},{"issue":"4","key":"3439_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/gut.36.4.615","volume":"36","author":"AM Brind","year":"1995","unstructured":"Brind AM, Bray GP, Portmann BC, Williams R. Prevalence and pattern of familial disease in primary biliary cirrhosis. Gut. 1995;36(4):615\u20137. https:\/\/doi.org\/10.1136\/gut.36.4.615.","journal-title":"Gut"},{"issue":"3","key":"3439_CR32","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","volume":"68","author":"MJ Mayo","year":"2023","unstructured":"Mayo MJ, Carey E, Smith HT, Mospan AR, McLaughlin M, Thompson A, et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis. Dig Dis Sci. 2023;68(3):995\u20131005. https:\/\/doi.org\/10.1007\/s10620-022-07581-x.","journal-title":"Dig Dis Sci"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03439-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03439-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:03:19Z","timestamp":1771268599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03439-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3439"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03439-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Sonal Kumar: Consultant: Gilead, Madrigal, GSK, Boehringer Ingelheim, Intercept Pharmaceuticals, Ipsen, Novo Nordisk; Speaker and\/or received honoraria from Madrigal, GSK, Novo Nordisk, Ipsen, Intercept Pharmaceuticals, Gilead; Nisreen Shamseddine: Employee of Ipsen; Hongbo Yang, Su Zhang, Dongni Ye, Shravanthi Seshasayee, Jingyi Chen: Employees of Analysis Group Inc., which received consulting fees from Ipsen; Kris V. Kowdley: Received grants from: Boston Scientific, Corcept, CymaBay, GENFIT, Gilead, GlaxoSmithKline, Hanmi, Intercept, Ipsen, Janssen, Madrigal, Mirum, Novo Nordisk, NGM, Pfizer, Pliant, Terns, Viking, Zydus, 89bio Inc.; Received royalties or licenses from UpToDate; Received consulting fees from: CymaBay, Enanta, GENFIT, Gilead, HighTide, Inipharm, Intercept, Ipsen, Madrigal, Mirum, NGM, Pliant, Pfizer, Protagonist, Zydus, 89bio Inc.; Received payment or honoraria from AbbVie, Gilead, Intercept; Received payment for expert testimony from the Department of Justice; Participant on a Data Safety Monitoring Board or Advisory Board for: CTI, Medpace, Labcorp, Worldwide Clinical Trials; Stockholder in Inipharm; Receipt of equipment, materials, drugs, medical writing, gifts, or other services from Velacur.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study used IQVIA Pharmetrics\n                      \u00ae\n                      Plus claims data obtained under license from IQVIA\n                      \u00ae\n                      , as per signed agreement between Ipsen and IQVIA\n                      \u00ae\n                      . The study was considered exempt research under 45 Code of Federal Regulations (CFR) \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7 164.514.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}